FDA grants Syndax breast cancer drug entinostat 'breakthrough' status
This article was originally published in Scrip
Syndax Pharmaceuticals revealed on 11 September the US FDA had granted breakthrough therapy designation to the company's experimental breast cancer drug entinostat, an experimental histone deacetylase inhibitor.
You may also be interested in...
The company says a subgroup of lung cancer patients with high pre-treatment monocyte levels showed promising response and PFS rates in study pairing Syndax’s selective HDAC inhibitor with Merck’s Keytruda. Mature data will inform future Phase III melanoma plans.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.